Tiziana Life Sciences, a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, has begun a strategic plan to change its corporate structure by establishing Tiziana Life Sciences as the ultimate parent company of the Tiziana Group while pursuing a direct listing on the Nasdaq. As part of the move, the company will no longer be headquartered in England or trade on the London Stock Exchange. Read more.
Tiziana Life Sciences Plans Nasdaq Direct Listing
